Experience

• 

  Apotex Inc.

  • Greater Toronto Area, Canada

  • Chief Corporate Development Officer

    • Sep 2023 - Present
    • Greater Toronto Area, Canada

    Apotex is the largest Canadian-based global pharmaceutical company. Our portfolio strategy is to provide affordable high-quality medicines and health solutions. We will continue to move up the value chain in select therapeutic categories, with complex generics, specialty therapeutics, and consumer health brands.As Chief Corporate Development Officer my focus is on portfolio strategy, diversifying our pipeline and entering new markets and geographies. This role oversees global business development, mergers and acquisitions, and strategic partnerships with a goal to accelerate Apotex’s business growth.

• 

  Sequoia Advisors Inc.

  • Greater Toronto Area, Canada

  • Managing Director

    • Apr 2014 - Present
    • Greater Toronto Area, Canada

    Director | Mentor | Coach - See Select Board Roles under Organizations

• 

  VIVO Cannabis Inc.

  • Toronto, Ontario, Canada

  • Chief Executive Officer

    • Oct 2017 - Dec 2020
    • Toronto, Ontario, Canada

    A TSX-listed vertically integrated cannabis business providing premium products and services to support health and well-being. VIVO has two licensed producers and a network of medical cannabis clinics in Canada, and operates international affiliates in Germany and Australia.

• 

  Merus Labs

  • Toronto

  • Chief Executive Officer

    • Sep 2014 - Sep 2017
    • Toronto

    Merus Labs is an international specialty pharmaceutical company focused on acquiring and optimizing legacy and growth products. European-focused with hubs in Zurich and Amsterdam. The Company leverages its expertise and scalable platform across Europe, Canada and select other markets to deliver value. On July 17, 2017 Merus Labs ceased to be a public (NASDAQ/TSX) company, and was acquired by Norgine B.V.

• 

  Teva Pharmaceuticals

  • Israel
  • Pharmaceutical Manufacturing
  • 700 & Above Employee

  • Chief Executive Officer

    • 2008 - Jan 2014

    Led generic and specialty pharmaceutical business units and all non-commercial functions (with full P&L accountability for up to $1 billion in annual revenue). Increased operating profit by 75% and market share by 70% in a 5 year period. Proven internal and external business influencer. Transformational leader. Acquisition experience.

  • Executive Vice President

    • 2003 - 2008

    Shaped first-to-market pipeline focus and sharpened go-to-market strategy. Strengthened pipeline, new product launch process and key strategic relationships.

• 

  Taro Pharmaceuticals

  • Toronto, Canada Area

  • Chief Executive Officer

    • 2000 - 2003
    • Toronto, Canada Area

    Tripled sales, strengthened talent and improved return on sales. Entered untapped markets and new business segments, with a focus on dermatolgy. Active participant in successful $100 million secondary offering.

• 

  Eli Lilly and Company

  • Toronto, Canada Area

  • Vice President of Marketing

    • 1983 - 2000
    • Toronto, Canada Area

    Selected for Lilly's top talent development program. Prior to VP Marketing, advanced through 8 cross-functional roles and 7 internal promotions (Financial Analyst, Human Resources Associate, Supply Manager, Financial Planning Manager, Associate Director Logistics, Controller Medical Device Division, Business Unit Director Generics and Hospital). Executed a game-changing life cycle management strategy for PROZAC.

• 

  Deloitte

  • Costa Mesa, California

  • Senior Associate

    • 1979 - 1982
    • Costa Mesa, California

    Focused on strategic consulting and auditing. Diverse clients ranged from Fortune 500 companies to the California Angels Baseball Club.